Search Results

You are looking at 1 - 10 of 27 items for :

  • "intraperitoneal chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Maurie Markman

intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy . Cancer Res 1989 : 49 : 3380 – 3384 . 10 Howell SB Pfeifle CE Wung WE . Intraperitoneal cisplatin with systemic thiosulfate protection . Ann

Full access

Robert F. Ozols

cancer . Cancer Treat Rep 1978 ; 62 : 1 – 11 . 8 Markman M . Intraperitoneal chemotherapy . Semin Oncol 1991 ; 18 : 248 – 254 . 9 Markman M Reichman B Hakes T . Evidence supporting the superiority of intraperitoneal cisplatin

Full access

Pankaj Singhal and Shashikant Lele

58 . 14. Kirmani S Braly PS McClay EF . A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer . Gynecol Oncol 1994 ; 54 : 338 – 344 . 15. Alberts DS Liu PY Hannigan EV

Full access

Keli Turner, Sheelu Varghese, and H. Richard Alexander

intraperitoneal chemotherapy (HIPEC), usually with mitomycin C or cisplatin, has been largely established as the best initial therapeutic intervention in selected patients with DMPM. The intent of operation with CRS and HIPEC is to remove all gross disease and

Full access

Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes

combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial . Lancet 2009 ; 374 : 1331 – 1338 . 20. Markman M Walker JL . Intraperitoneal chemotherapy of ovarian cancer: a review

Full access

Deborah K. Armstrong

confirmatory North American trial, Dr. Armstrong added. Intraperitoneal Chemotherapy Patients with low-volume disease (after optimal surgical debulking) benefit from intraperitoneal delivery of chemotherapy, but it increases toxicity and requires strong

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

postoperative therapy in patients who have received NACT and IDS ( supplemental eTable 3 ). Given the lack of survival improvement in OV21/PETROC, more data are needed to establish whether postoperative intraperitoneal chemotherapy provides clinical benefit in

Full access

Leigh Selesner, Gabrielle Gauvin, Dorotea Mutabdzic, Eileen O’Halloran, Maxwell Kilcoyne, Kwan-Keat Ang, Jeffrey Farma, Elin Sigurdson, and Sanjay Reddy

Introduction: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has led to improved survival in select patients with peritoneal surface malignancies. Predicting the volume of disease and any unresectable disease is

Full access

Robert J. Morgan Jr

all treatment approaches that have been shown to improve overall outcomes in this very lethal and morbid illness. Treatment with intraperitoneal chemotherapy has been shown to confer the best overall outcomes; however, surprisingly, it has not yet been

Full access

Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim

Edited by Kerrin G. Robinson

Ovarian cancer is the fifth most common cause of cancer-related death among women in the United States, although the median survival of patients has been increasing over the past few decades. In patients with epithelial ovarian cancer, chemotherapy has increased survival. Platinum agents combined with taxanes have become standard treatment. Intraperitoneal chemotherapy has also increased survival. Cytoreductive surgery to optimally debulk a tumor or, ideally, remove any gross disease has also been shown to increase survival. Each 10% increase in cytoreduction correlates with a 5.5% increase in median survival. The ability to successfully perform optimal cytoreduction ranges from 20% to 90%. Many institutions have recently begun to perform aggressive/ultraradical procedures to achieve this result. Interval cytoreduction may also benefit patients whose initial surgery is suboptimal, especially if the first procedure was performed by a surgeon unfamiliar with the disease. Secondary cytoreduction can increase survival in patients with low-volume disease and a long disease-free interval. All of these procedures should be performed by a specialist trained in ovarian cancer surgery.